The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics

Citation
McMurray JJV, DeMets DL, Inzucchi SE, et al. Eur J Heart Fail 2019;21:1402–11.